Cardiovascular and interventional radiology · 2025
Tumor Dose as an Oncologic Predictor of Outcome in Patients with HCC Treated with Resin Y90 Microspheres.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dabbous Howard, Gad Sandra, Mohnasky Michael, Villalobos Alex, Brandon David, Xing Minzhi, Kokabi Nima
Аннотация
OBJECTIVE: To evaluate tumor dose (TD) as a predictor of oncological outcomes in patients with hepatocellular carcinoma (HCC) treated with resin Y90 radioembolization (RE), and to evaluate non-tumoral liver dose (NTLD) as a predictor of treatment-related toxicity.
METHODS: A single-center retrospective review of treatment-naïve HCC patients who underwent resin-based Y90 between 2019 and 2022 was conducted. Baseline demographics, clinical history, and adverse events per CTCAE v5.0 were analyzed. Baseline imaging and post-treatment imaging were also evaluated using Response per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for tumor response.
RESULTS: 78 patients (mean age:66.7 years) with 91 tumors underwent Y90-RE, with a median follow-up period of 28.3 months; 23 received lobar Y90-RE, while 55 patients received segmentectomies. Mean TD for the entire cohort was 336.6 ± 291.9 Gy. Mean TD was significantly higher in segmental Y90-RE (424.3 Gy) vs lobar Y90-RE (203.7 Gy) (p < 0.001). At 3 months, 98% of segmentectomy and 72% of lobar patients achieved an objective response (OR), with 90% and 40% achieving complete response (CR), respectively. At 6 months, 97% and 94% of segmentectomy patients achieved OR and CR, compared to 84% and 68% in lobar patients. Mean tumor dose > 250 Gy predicted prolonged overall and progression free survival. A mean NTLD dose of 103 Gy predicted grade 3 + adverse events in lobar treatments.
CONCLUSION: In patients with HCC treated with resin-based Y90-RE, personalized dosimetry is a key factor in ensuring favorable oncological outcomes. Level of evidence Level 3b, retrospective cohort study.
METHODS: A single-center retrospective review of treatment-naïve HCC patients who underwent resin-based Y90 between 2019 and 2022 was conducted. Baseline demographics, clinical history, and adverse events per CTCAE v5.0 were analyzed. Baseline imaging and post-treatment imaging were also evaluated using Response per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for tumor response.
RESULTS: 78 patients (mean age:66.7 years) with 91 tumors underwent Y90-RE, with a median follow-up period of 28.3 months; 23 received lobar Y90-RE, while 55 patients received segmentectomies. Mean TD for the entire cohort was 336.6 ± 291.9 Gy. Mean TD was significantly higher in segmental Y90-RE (424.3 Gy) vs lobar Y90-RE (203.7 Gy) (p < 0.001). At 3 months, 98% of segmentectomy and 72% of lobar patients achieved an objective response (OR), with 90% and 40% achieving complete response (CR), respectively. At 6 months, 97% and 94% of segmentectomy patients achieved OR and CR, compared to 84% and 68% in lobar patients. Mean tumor dose > 250 Gy predicted prolonged overall and progression free survival. A mean NTLD dose of 103 Gy predicted grade 3 + adverse events in lobar treatments.
CONCLUSION: In patients with HCC treated with resin-based Y90-RE, personalized dosimetry is a key factor in ensuring favorable oncological outcomes. Level of evidence Level 3b, retrospective cohort study.